Opioid prescription use is increasing. Narcotic bowel syndrome (NBS) refers to chronic abdominal pain aggravated by narcotic use. Despite increasing narcotic use, NBS may be under-recognized. The aim of this study was to assess whether gastrointestinal (GI) symptoms in the community are associated with chronic narcotic use and estimate the likely prevalence of NBS.
INTRODUCTION
Opioid analgesics are the mainstay of therapy in patients with chronic cancer pain and may represent the only source of relief for many patients with moderate-to-severe nonmalignant pain (1, 2) . However, adverse e ects can compromise the usefulness of these agents for analgesia. As opiates a ect gastrointestinal (GI) motility through the mu-receptor (1,3 -5) , bowel dysfunction is the most important and distressing adverse e ect. Opioid bowel (or GI) dysfunction is manifested by symptoms, such as constipation, nausea, bloating, ileus, and sometimes worsening abdominal pain (4, 6) . e e ects of opioids on bowel function have been best studied in patients with cancer pain. For example, in a prospective study of 1,635 cancer patients referred to a pain clinic, cancer-related constipation was reported by 33 % of patients (7) . However, the prevalence of adverse GI e ects has not been extensively evaluated in outpatients with chronic nonmalignant pain.
Narcotic bowel syndrome (NBS) is a recognized subset of opioid bowel dysfunction that is characterized by chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics (8, 9) . is syndrome is thought to be under-recognized, but is probably becoming more prevalent because of an increase in the use of narcotics for chronic nonmalignant painful disorders in United States (4, 6, 10) , and the paradoxical development of increased pain in those chronically taking opiates associated with maladaptive behaviors (11, 12) . However, to our knowledge, there are no epidemiological data on the prevalence of NBS in the US community or elsewhere.
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us, we aimed to evaluate whether bowel dysfunction is associated with chronic narcotic use and estimate the prevalence of NBS in the general US population.
METHODS

Participants
e Olmsted County (MN) population comprises 124,277 persons (US Census 2000 data), of whom 89 % are white; sociodemographically, the community is very similar to the US white population (13) . Over 95 % of County residents receive their medical care from one of the two group practices (Mayo Medical Center and Olmsted Medical Center). e Mayo Clinic has maintained a common medical record system with its two a liated hospitals (Saint Marys and Rochester Methodist) for over 90 years. Recorded diagnoses and surgical procedures are indexed, including the diagnoses made for outpatients seen in o ce or clinic consultations, emergency room visits or nursing home care, as well as the diagnoses recorded for hospital inpatients. is system was further developed by the Rochester Epidemiology Project (14) . Annually, over 80 % of the entire population is attended by one or both of these two practices, and 96 % of the entire population is seen at least once during any given 4-year period (13) . e REP medical records linkage system provides what is essentially an enumeration of the population, from which random samples can be drawn. Following approval by the institutional review boards of the Mayo Clinic and Olmsted Medical Center, we used this system to draw a series of random samples of Olmsted County residents strati ed by age (5-year intervals between 20 and 94 years) and gender (equal numbers of men and women).
A randomly identi ed subset of Olmsted County residents were mailed a revision of the study questionnaire (14 -18) . Speci cally participants who had died, moved from the County, and those who had not responded (or explicitly refused to respond to an earlier follow-up survey (19) ) were not eligible for this study survey. A total of 4,954 residents of Olmsted County were mailed the study questionnaire in 2002 -2004, and reminder letters were mailed at weeks 2, 4, and 7 to nonresponders. Participants who indicated at any point that they did not wish to complete the survey were not contacted further. Otherwise, non-responders were contacted by telephone at week 10 to request their participation and verify their residence within the County. A completed questionnaire was returned by 2,913 participants, giving a response rate of 59 % .
Case defi nition of NBS and data collection
We reviewed all medication lists in the clinical documentation of the 2,913 participants who completed the questionnaire, in 2002 -2004. We found 117 participants who were taking any prescription narcotics. e clinical records of all these participants were reviewed by one physician (RSC) from the rst date of narcotic prescription until December 31, 2007 , to identify all potential cases of NBS. To identify all potential cases of NBS, demographic data as well as clinical data of participants taking narcotics were reviewed from the complete medical records, including every inpatient and outpatient visit.
Chronic narcotic use and NBS were de ned by speci c criteria, as follows:
Chronic narcotic use . is refers to taking any opioid drug for ≥ 5 weeks for the treatment of chronic or acute pain of malignant or nonmalignant origin (4) .
NBS
. is refers to episodes of abdominal pain that resulted in inpatient or outpatient visits, and narcotic use for >2 weeks (9, 20) . Among the potential cases, two diagnostic de nitions were applied:
(1) De nite NBS : De ned as all of the following -chronic abdominal pain (more than 1 month) (8) in the setting of continued or escalating dosages of narcotics; the pain worsens or incompletely resolves with continued or escalating dosages of narcotics; there is marked worsening of pain when the narcotic dose wanes and improvement when narcotics are reinstituted; there is a progression of the frequency, duration and intensity of pain episodes; and the nature and intensity of the pain is not explained by a current or earlier GI diagnosis (20) .
(2) Probable NBS : Narcotics use (>2 weeks), new abdominal pain leading to any inpatient or outpatient visits, and the nature and intensity of the pain were not explained by a current or earlier GI diagnosis (20) .
Survey for GI symptoms in participants taking and not taking narcotics
A total of 2,913 residents of Olmsted County responded to the study questionnaire in 2002 -2004. e questionnaires used (Talley bowel disease questionnaires, BDQs) have been shown to be understandable, easily completed, and to have adequate validity (17, 18) . e BDQ consists of 46 GI symptoms and the somatic symptom checklist. e somatic symptom checklist consists of 12 non-GI illnesses, and participants are instructed to indicate how o en each symptom occurred (0 = not a problem to 4 = occurs daily) and how bothersome each was (0 = not a problem to 4 = extremely bothersome when it occurs) during the past year, using separate 5-point scales (21, 22) . In addition, we asked about any laxative use on the questionnaire.
Charlson comorbidity index
e Charlson comorbidity index (23, 24 ) is a weighted sum of 17 speci c chronic diseases adapted by the Rochester Epidemiology Project for use based on the electronic medical index using ICD9-CM codes.
Statistical analysis
We estimated the age-and sex-adjusted prevalence of NBS in the community, adjusting to the distribution of the US population of 2000. e 95 % CIs for the prevalence of NBS were estimated, assuming a binomial distribution for cases. For analyzing opioid bowel dysfunction, we identi ed symptom prevalence on the questionnaire in those with and without chronic narcotic
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Opioid Bowel Dysfunction use. Logistic regression models were examined, in which each individual symptom was considered as the dependent variable and chronic narcotic use (as a dummy regression variable) as the primary predictor variable. All P values were two-sided, and P values < 0.05 were considered statistically signi cant.
RESULTS
A total of 4,954 participants who were originally sampled at random from among all residents of Olmsted County were mailed the questionnaire, and 2,913 returned a completed questionnaire, giving an overall response rate of 59 % . e mean age of respondents was 62 years, and 52 % were female. Using a logistic regression model for response (no / yes), a weak association with age was detected (odds ratio for responding, per year of age = 1.016 (95 % CI: 1.012, 1.020), but no association with gender (odds ratio in females relative to males = 1.1 (95 % CI: 0.99, 1.22)).
NBS
Among the 2,913 participants, 117 participants were found to be taking prescription narcotics on a review of their medical charts. e prevalence of chronic narcotic users in the community was 4.0 % (95 % CI: 3.3, 4.5). Among these 117 participants, 12 participants (10.3 % ) were on narcotics for malignant pain, and 107 for non-malignant pain, including musculoskeletal pain, post-surgery pain, vascular pain, pain of connective tissue origin, and other disease ( Figure 1 ).
Medical records for the 117 participants with any narcotic use were further reviewed to identify whether any of them developed new-onset NBS a er the prescription of narcotics. None of the participants met the criteria for de nite NBS, but ve participants met the criteria for probable NBS, yielding a prevalence of probable NBS of 0.17 % (95 % CI: 0.06, 0.40).
Opioid bowel dysfunction
Among the 117 participants with narcotic use, we identi ed 32 patients who took narcotics for < 5 weeks, and a further 33 patients had begun narcotic use a er the survey. us, 52 participants who met the criteria for chronic narcotic use before the survey were included in the analysis of opioid bowel dysfunction. ose identi ed as chronic narcotic users had a mean age of 72 ( ± 9) years, and 71 % were female. Among 52 participants with chronic narcotic use, 37 cases (71.2 % ) had received a daily opioid dose equivalent to ≥ 10 mg of oral morphine. Table 1 summarizes the demographic characteristics of participants with and without chronic narcotic use. e participants taking chronic narcotics were older and a greater proportion of them were female, in contrast to participants without chronic narcotic use. In addition, somatic symptom checklist scores and the Charlson comorbidity score were signi cantly associated with chronic narcotic use (both P < 0.005). Notably, use of laxatives was signi cantly associated with chronic narcotic use ( P < 0.05). However, chronic narcotic users were similar to nonusers with respect to smoking history, alcohol history, marital status, educational level, and body mass index ( Table 1 ).
e distribution of individual GI symptoms in participants with or without chronic narcotic use is summarized in Table 2 . As expected, symptoms of constipation, including straining, hard stools, and infrequent bowel movements, were more frequently reported by participants taking chronic narcotics. Interestingly, diarrhea-related symptoms including urgency, loose bowel movements, and frequent bowel movements, also were more frequently reported by participants on chronic narcotics. In addition, other GI symptoms, including nausea, heartburn, abdominal pain, and abdominal bloating, were common in participants with chronic narcotic use.
Unadjusted logistic regression analysis showed that acid regurgitation, nausea, abdominal bloating, abdominal pain, straining, feelings of incomplete evacuation, urgency, loose bowel movements, and frequent bowel movements were signicantly associated with chronic narcotic use ( Table 3 ) 
FUNCTIONAL GI DISORDERS
a er adjusting for age, gender, somatic symptom checklist score, and laxative use, only increased odds for frequent abdominal pain and frequent stools remained signi cant ( Table 3 ) .
DISCUSSION
e possible relationship between narcotic use and symptoms of functional bowel disorders has recently garnered major attention, in part because of a substantial increase in opioid prescription in the United States in recent years (20, 25) . ere have thus been growing concerns about the impact of unintended GI side e ects of opiates in the general population, but to our knowledge no data have been available regarding the prevalence of NBS in the community (4) . In this study, we found that NBS in the community is probably relatively rare, although those using prescription narcotics chronically report more GI symptoms and use more laxatives. However, we may have missed some cases; as laxative use was two-fold greater in the chronic narcotic use population, it seems logical that some patients simply initiated laxatives for treatment of narcoticassociated constipation without going through an additional outpatient or inpatient visit. A low dose of narcotic may not 
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Opioid Bowel Dysfunction no International Classi cation of Disease (ICD) code and is not included in the most recent categorization of the functional GI disorders (27) . Notably, however, our study identi ed only ve cases (0.17 % ) of NBS in a community sample of 2,913 participants. Still, we can conservatively calculate on the basis of our results that about 142,587 people in the United States may have NBS (applying the age-and sex-speci c proportions of participants identi ed with NBS in this study to the corresponding age-and sex-speci c population totals of US whites in 2000)
. e e ects of opioids on bowel function have been well documented in patients with cancer pain; the prevalence of opioidinduced constipation has been reported to range from 20 to 40 % in patients with malignant or nonmalignant pain (28 -30) . Among patients being treated with opioids, 8 -40 % also report nausea or vomiting (3, 31, 32) . A meta-analysis of randomized, placebo-controlled trials in non-cancer patients receiving opioids for pain revealed that ~ 80 % of patients experienced at least one adverse event, with constipation (41 % ) and nausea (32 % ) being the most common opioid-related side e ects (29) . However, it is very di cult to obtain an accurate estimate of the impact of opioid therapy on GI symptoms in the community because of numerous other co-morbidities. e background health status of the patient, including mobility, diet, and other medications, may in uence whether or not an opioid induces signi cant GI side e ects. We observed that participants taking narcotics chronically had more GI symptoms compared with those not on this drug class, but we did not detect any signicant di erences in the prevalence of most GI symptoms once age, gender, and laxative use were taken into account aside from frequent abdominal pain and diarrhea (more frequent stools).
e diarrhea reported may actually re ect fecal seepage or incontinence with over ow from fecal impaction, although this could not be discerned from the questionnaire data provided. e strengths of this study include the investigation of a random community sample. e participants were not necessarily seeking health care for their GI complaints, which should have minimized the selection bias, and this sample provided an excellent opportunity to study the relationship between narcotic use and GI symptoms. A validated questionnaire was applied and a chart review was used to assess prescription narcotic usage.
is study also has a number of important limitations. We were not able to evaluate illicit drug use in this sample although it is probably low. Our data may not be generalizable to the whole US population because the racial composition of this community is predominantly white.
e prevalence of GI symptoms may vary by ethnic group, but at a minimum our data are probably generalizable to the US white population. In addition, our study relied on the medical chart to determine the prevalence of NBS; it is conceivable that there is under-reporting of opioid-induced bowel dysfunction, including abdominal pain, by physicians. Although mild GI symptoms may not be recorded on each patient visit, we assume that more severe symptoms would have been charted. Finally, the abdominal pain and bowel dysfunction observed could be due to non-narcotic issues that were not coded. us, the underlying disease induce NBS, but among 52 participants prescribed narcotics, most (37 patients or 71 % ) had received a dosage of narcotics (a daily opioid dose equivalent to >10 mg of oral morphine) that is classi ed as high in the literature (4) . As we carried out a retrospective study based on the medical chart, our application of an arbitrary de nition from the literature may have underestimated the prevalence of NBS because we would not have identi ed cases that did not present for medical care. On the other hand, as Olmsted County residents almost exclusively have their health care delivered in a system that captures all encounters, and almost all residents see their physician at least once every few years, this bias is unlikely to be very large; any really signi cant symptomatology is unlikely to go unnoticed and uncharted by the system in place.
Chronic pain may o en be poorly managed in clinical practice. Opioids are used extensively for treating moderate to severe pain secondary to malignancy, but narcotic prescription patterns for nonmalignant pain also seem to be increasing. Pletcher et al . (25) reported that opioid prescription for patients making a pain-related visit to the emergency department changed a er the national quality improvement initiatives in the late 1990s. Speci cally, they observed that opioid prescription for pain-related visits increased from 23 % in 1993 to 37 % in 2005. We found that 4.0 % of the Olmsted County community is taking prescription narcotics, and the majority of participants using narcotics are taking them for non-malignant pain-related reasons; only 8.5 % on narcotics were prescribed for malignancy in this study. It is conceivable that narcotic prescription in the community will continue to increase, and therefore we are obliged to understand the impact of these medications on GI health.
Narcotic bowel syndrome was rst described by Sandgren et al . (8) in 1984. ey observed ve patients who apparently had a distinct syndrome comprising chronic abdominal pain, vomiting, weight loss, and features of intestinal pseudo-obstruction associated with prolonged abuse of narcotic analgesics; the symptoms resolved rapidly in all patients when narcotic administration was stopped. In an editorial in 1989, Rogers et al . (9) proposed that NBS be de ned as chronic abdominal pain associated with prior narcotic intake in moderate-to-heavy doses over a time period of 2 weeks. It was further suggested that this syndrome is an o en overlooked cause of chronic abdominal pain and intestinal pseudo-obstruction (9) . In a recent case series, four patients with NBS were identi ed over a 20-year period; the authors (20) suggested that NBS may now be becoming more prevalent because of increased use of narcotics for chronic non-malignant painful disorders. ey further proposed revised diagnostic criteria (20) ; the review emphasized the presence of chronic or frequently recurring abdominal pain that is treated with increasingly high doses of chronic opiates, creating a viscous cycle in which escalating narcotic use worsens rather than relieves symptoms. However, little other literature exists, with earlier publications comprising only case reports (8, 20, 26) . e lack of epidemiological data may represent poor recognition of the syndrome by clinicians, or the fact that this syndrome has
that the narcotics were being prescribed for could be the explanation for the symptoms recorded. We also cannot exclude the presence of possible functional bowel disorders such as IBS as a cause of the patient ' s pain.
We conclude from this careful albeit retrospective population-based study (including a detailed chart review) that NBS in the community is probably relatively rare, although some under-reporting bias cannot be totally excluded. ose with chronic narcotic use appear to report more GI symptoms, but this seems to be explained by other factors, including increased use of laxatives. Further study is required to better de ne the epidemiology of opioid bowel dysfunction, including NBS, in nonmalignant patients, and clarify the appropriate treatment strategies in the clinical setting.
